Floatz logo

Dc-Cik

Metastatic Gastric Carcinoma

M.D. Anderson Cancer CenterCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Metastatic Gastric Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 1/2CCC
Talzenna
National Cancer Institute (NCI)
Phase 2CCC
Inno-206
City of Hope Medical Center
Phase 1CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 1CC
Zn-C3
National Cancer Institute (NCI)
Phase 1CC

View all 12 →

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →